Description
Vinpocetine-Welfarm Pharmacodynamics
Improves brain metabolism by increasing glucose and oxygen uptake by brain tissue. Increases resistance of neurons to hypoxia by enhancing glucose transport to the brain, across the blood-brain barrier; shifts glucose breakdown to a more energy-saving aerobic pathway; selectively blocks calcium-dependent phosphodiesterase; increases levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) of the brain.
Increases the concentration of adenosine triphosphate (ATP) and the ATP/AMP ratio in brain tissue;
Increases brain noradrenaline and serotonin metabolism; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.
Reduces platelet aggregation and increased blood viscosity; increases the deformability of red blood cells and blocks red blood cell utilization of adenosine; increases red blood cell oxygen recoil. Enhances the neuroprotective effect of adenosine.
Increases cerebral blood flow; reduces cerebral vascular resistance without significant changes in systemic blood flow (blood pressure, minute volume, heart rate, total peripheral resistance). Not only it does not have the effect of “stealing”, but also increases the blood supply, primarily in the ischemic parts of the brain with low perfusion.
Indications
Neurology. Symptomatic therapy of the consequences of ischemic stroke, vascular vertebrobasilar insufficiency, vascular dementia, atherosclerosis, cerebral blood vessels, post-traumatic, hypertensive encephalopathy.
Ophthalmology. Chronic vascular diseases of the retina and choroid.
Otology. Hearing loss of the perceptual type, Meniere’s disease, tinnitus.
Contraindications
– Hypersensitivity to vinpocetine or other components of the drug;
– acute phase of hemorrhagic stroke;
– Severe form of coronary heart disease;
– severe heart rhythm disorders;
– pregnancy, breastfeeding;
– children under 18 years of age (due to lack of clinical trial data);
– rare hereditary galactose intolerance (galactosemia),
lactose intolerance, lactase deficiency, glucose-galactose malabsorption (due to the presence of lactose in the drug).
Caution
Precautions must be observed in patients with prolonged QT interval syndrome or in concomitant use with drugs that cause prolongation of this interval (periodic electrocardiography (ECG) monitoring is required).
Administration during pregnancy and breastfeeding
The drug is contraindicated in pregnancy and during breastfeeding.
Pregnancy:
Vinpocetine penetrates through the placenta, but the plasma concentration in the placenta and in the fetus is lower than in the mother. Teratogenic and embryotoxic effects have not been revealed. In animal studies, placental bleeding and spontaneous abortions have occurred at high doses (presumably due to increased
placental blood flow).
Breast-feeding period:
Within one hour, 0.25% of the administered dose of the drug will penetrate into the breast milk. If a decision to cancel breastfeeding or to refuse vinpocetine treatment, the benefit of breastfeeding for the baby and the benefit of therapy with vinpocetine for the woman should be compared.
Dosage and administration
- Inside, after a meal.
- The course of treatment and dosage is determined by the attending physician.
- Usually, the daily dose is 15-30 mg (5-10 mg three times a day).
- The initial daily dose is 15 mg. The maximum daily dose is 30 mg.
- The therapeutic effect develops approximately one week after the start of the drug. It takes three months to achieve full therapeutic effect. In case of kidney and liver diseases, the drug is prescribed in the usual dose; the absence of cumulation allows long courses of treatment.
